9 results · 20ms · Sources: EU EUDAMED, US FDA

Get notified when this changes

We'll email you when new records match this search — new devices, new clearances, certificate changes, or withdrawals.

Ingenia Ambition S and Ingenia Ambition X

FDA 510(k)
FDA Class 2 ·Radiology

ADVANCE A-CLASS TIBIAL INSERT

FDA 510(k)
FDA Class 2 ·Orthopedic

WINGMAN EXTENDABLE TIP SUPPORT CATHETER

FDA 510(k)
FDA Class 2 ·Cardiovascular

RESERVOIR 1.8ML

FDA Adverse Event
Malfunction ·MEDTRONIC PUERTO RICO OPERATIONS CO.·Product code FRN·October 17, 2014

ENDOPATH 5MM CURVED

FDA Adverse Event
Injury ·ETHICON ENDO-SURGERY, LLC.·Product code GEI·June 21, 2013

FREESTYLE NAVIGATOR

FDA Adverse Event
Malfunction ·Product code LFR·July 27, 2011

SPYSCOPE DS II ACCESS & DELIVERY CATHETER

FDA Adverse Event
Malfunction ·BOSTON SCIENTIFIC CORPORATION·Product code FBN·September 30, 2020

SPYSCOPE DS II ACCESS & DELIVERY CATHETER

FDA Adverse Event
Malfunction ·BOSTON SCIENTIFIC CORPORATION·Product code FBN·September 23, 2020

Boston Scientific COGNIS CRT-D, Cardiac Resynchronization Therapy Defibrillator, models N118, N119. The following models are not available in the US: models N106, N107, P106, P107. Sterilized using ethylene oxide. Product Usage: Boston Scientific cardiac resynchronization therapy defibrillators (CRT-Ds) are indicated for patients with moderate to severe heart failure who remain symptomatic despite stable, optimal heart failure drug therapy and have left ventricular dysfunction and QRS duration > or equal to 120 ms. This family of pulse generators provide a variety of therapies including: -Ventricular tachyarrhythmia therapy, which is used to treat rhythms associated with sudden cardiac death such as VT and VF; -Cardiac Resynchronization Therapy (CRT), which treats heart failure by resynchronizing ventricular contractions through biventricular electrical stimulation; -Bradycardia pacing, including adaptive rate pacing, to detect and treat bradyarrhythmias and to provide cardiac rate support after defibrillation therapy.

FDA Enforcement
Class II ·Terminated·Boston Scientific CRM Corp·October 29, 2014